期刊文献+

新辅助化疗联合保肢治疗骨肉瘤合并病理性骨折 被引量:10

New adjuvant chemotherapy combined with limb salvage for osteosarcoma combined with patho- logic fracture
原文传递
导出
摘要 目的分析新辅助化疗联合保肢术治疗骨肉瘤合并病理性骨折的疗效。方法选择新辅助化疗基础上行保肢治疗的骨肉瘤合并病理性骨折患者68例为联合组,同期单纯手术治疗而未接受化疗或仅接受术后化疗的骨肉瘤合并病理性骨折患者22例为非化疗组,同期无病理性骨折在新辅助化疗基础上行保肢治疗的骨肉瘤患者48例为无骨折组,骨肉瘤合并病理性骨折行截肢治疗的患者32例作为截肢组。比较各组患者生存率、局部复发率、转移率及生存质量。结果联合组平均预计生存时间较非化疗组显著延长(P〈0.05);较无骨折组、截肢组差异无统计学意义。各组5年生存率比较,联合组较非化疗组显著增高(P〈0.05),较无骨折组、截肢组差异无统计学意义;非化疗组较截肢组、无骨折组显著降低(P〈0.05)。联合组局部复发率较非化疗组显著降低(P〈0.01);较无骨折组、截肢组差异无统计学意义。联合组转移率较非化疗组显著降低(P〈0.01);较非骨折组、截肢组差异无统计学意义。联合组社会功能评分显著高于截肢组(P〈0.01);生理职能较非化疗组、截肢组均显著增高(P〈0.05);总体健康较非化疗组显著增高(P〈0.05);其余各项评分各组比较差异均无统计学意义。结论新辅助化疗联合保肢治疗骨肉瘤合并病理性骨折在保证患者生存率的前提下保存了肢体,并且不增加局部复发率及转移率,还可提高患者的毕存腈骨县治疗骨肉瘤合并病理忡骨析的合理方法. Objective To analyze the curative effect of neoadjuvant chemotherapy combined with limb salvage for osteosareoma with pathologic fracture. Methods The cases were divided into com- bined group (68 cases of osteosareoma with pathologic fracture who received limb salvage after neoadju- vant chemotherapy) , non-chemotherapy group (22 cases of osteosarcoma with pathologic fracture who re- ceived operation without concurrent chemotherapy or chemotherapy only after operation ) , non-fracture group (48 cases of osteosarcoma without synchronous pathologic fracture who received limb salvage after neoadjuvant chemotherapy) and amputation group (32 cases of osteosareoma combined with pathologic fracture who received amputation). Survival rate, local recurrence rate, metastasis rate and quality of life were compared between groups. Results Average estimated survival period of the combined group was obviously longer than that of the non-chemotherapy group ( P 〈 0.05 ) , but had no significant difference from the non-fracture group or amputation group. Of the 5-year survival rate between groups, the com- bined group was evidently higher than the non-chemotherapy group ( P 〈 0.05 ) , but without significant difference from the non-fracture group or amputation group. Whereas, non-chemotherapy group showed a lower 5-year survival rate than the amputation group or non-fracture group ( P 〈 0.05 ). Localized recur- rence rate and metastasis rate of the combined group were markedly decreased when compared to the non- chemotherapy group ( both P 〈 0.01 ), but were not significantly different from the non-fracture group or the amputation group. The combined group showed a significantly higher score of social function than the ampu- tation group ( P 〈 0.01 ) , a significantly higher score of biological pofession than the non-chemotherapy group or the amputation group (P 〈 0.05 ), and a significantly higher score of general health than the non- chemotherapy group (P 〈 0. 05 ). However, no significant differences were observed between groups regarding the scores for other items. Conclusion New adjuvant chemotherapy combined with limb salvage is a rational treatment of osteosarcoma with pathologic fracture for it saves the limb after the guarantee of survival rate without increasing the localized recurrence rate or metastasis rate, and improves quality of life.
出处 《中华创伤杂志》 CAS CSCD 北大核心 2013年第4期334-337,共4页 Chinese Journal of Trauma
关键词 骨折 自发性 骨肉瘤 抗肿瘤联合化疗方案 Fractures, spontaneous Osteosarcoma Antineoplastic combined chemotherapyprotocols
  • 相关文献

参考文献10

  • 1Rosen G, Caparros B, Huvos AG, et al. Preoperative chemothera- py for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preop- erative chemotherapy. Cancer, 2002, 49 (6) : 1221 - 1230.
  • 2Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer, 2011,47(16) :2431 -2445.
  • 3Bacci GB, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosareoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by eisplatin and doxorubicin. Cancer, 1993, 72 ( 11 ) :3227 - 3238.
  • 4Kraybi11 WG, Harris J, Spiro IJ, et al. Long - term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high - risk, high - grade, soft tissue sarcomas of the extremities and body wall. Cancer, 2010, 116(19) :4613 -4621.
  • 5Scully SP, Ghert MA, Zurakowski D, et al. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications. J Bone Joint Surg ( Am), 2010, 84 ( 1 ) :49 -57.
  • 6Furguson PC, McLaughlin CE, Griffin AM, et al. Clinical and functional outcomes of patients with a pathologic fracture in high - grade osteosarcoma. J Surg Oncol, 2010, 102(2) :120-124.
  • 7Kim MS, Lee SY, Lee TR, et al. Prognostic effect of pathologic fracture in localized osteosarcoma: a cohort/case controlled study at a single institute. J Surg Oncol, 2009, 100(3) :233 -239.
  • 8Abudu A, Sferopoulos NK, Tillman RM, et al. The surgical treat- ment and outcome of pathological fractures in localised osteosarco- ma. J Bone Joint Surg (Br) , 1996, 78 (5) :694 -698.
  • 9Papagelopoulos PJ, Mavrogenis AF, Savvidou OD, et al. Pathological fracture in primary bone sarcomas. Injury, 2008, 39(4) :395 -403.
  • 10Ottaviani G, Robert RS, Huh WW, et al. Functional, psyehoso- cial and professional outcomes in long - term survivors of lower - extremity osteosarcomas: amputation versus limb salvage. Cancer TreatRes, 2009, 152:421 -436.

同被引文献107

引证文献10

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部